Sep 12, 2022 / 05:30PM GMT
Operator
My name is Jason, and I will be your conference facilitator today for Amgen's investor conference call from the European Society of Medical Oncology 2022 Congress. (Operator Instructions) I would now like to introduce David Reese, Executive Vice President of Research and Development. Dr. Reese, you may now begin.
David M. Reese - Amgen Inc. - EVP of Research & Development
Thanks, Jason, and welcome, everyone. We had a couple of important LUMAKRAS data sets presented here in Paris earlier today, and I know there's an intense interest in both the lung cancer and colorectal data sets. So we'll move into the program presentation in just a moment.
Can we go to the next slide, please? Here's our safe harbor statement in the next slide. And then one more slide. So today, I'll provide a very brief introduction and then Dr. John Strickler from Duke will give an overview of the colorectal cancer data, LUMAKRAS in combination with Vectibix. And then Ferdinandos Skoulidis will provide an overview of the CodeBreaK 200 Phase III confirmatory trial in non-small
Amgen Inc Corporate Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot